In contrast, hormone receptor-positive (HR+) BC typically shows minimal immune infiltration, requiring different approaches to stimulate immune responses, such as targeting tumor-associated macrophages or using cytokine-based therapies to attract immune cells to the tumor site. Here, NR4A1 is linked to neoplasm.